​Sponsor: University of Oxford
EudraCT number: 2012-000616-28

Eurosarc Trial of Linsitinib in advanced Ewing Sarcoma

Study Status

Closed to recruitment

This is a multi-centre, single arm Phase II study, utilising Bayesian analysis


Sponsor: University of Oxford
EudraCT number: 2011-003169-13

A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma

Further information about this trial can be found on the CRUK website.


Sponsor: University of Oxford
EudraCT number: 2012-003762-40

A CR-UK phase I study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy.

To determine the safety, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of BKM120 when administered concomitantly with thoracic radiotherapy in patients with metastatic NSCLC.

Study Status

Completed recruitment. Many thanks to the trial team at the Churchill Hospital for their hard work during the trial.


Sponsor: University of Oxford
Clinical Number: NCT02145416

Anal squamous cell carcinoma: Investigation of functional imaging during Chemoradiotherapy (CRT)

Study Design

A single centre observational study to evaluate changes in functional images (MRI, Perfusion - CT, & FDG PET) after treatment with chemoradiotherapy.

Study Population

Patients undergoing radical CRT for anal cancer in Oxford University Hospitals NHS Trust.


ATR inhibitor and chemoradiotherapy in oesophageal cancer.

This study will test the combination of a novel ATR inhibitor with radiotherapy or chemoradiotherapy in oesophageal cancer. The design is a phase I, open-label, multicentre, 3-stage, schedule-finding trial using TiTE-CRM (Time-to-Event Continual Reassessment Method).

The study is in setup with a planned opening date of May 2016. A CRUK New Agents Committee grant has been awarded for this study (CRUKD/15/011). Site selection will include Oxford, Leeds & Glasgow.


About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.
Subscribe to Department of Oncology RSS